Clinical Trials Sponsored by Newron Pharmaceuticals SPA

Total 130 results

Newron Pharmaceuticals SPA

Completed

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Schizophrenia

India, United States
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease
Newron Pharmaceuticals SPA

Unknown

An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

Healthy

United Kingdom
Newron Pharmaceuticals SPA

Completed

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Schizophrenia

United States
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Idiopathic Parkinson's Disease

Italy
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Terminated

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms (STARS)

Rett Syndrome

United States, India, United Kingdom, Australia, Italy
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Newron Pharmaceuticals SPA

Completed

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Chronic Schizophrenia

United States, India
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Newron Pharmaceuticals SPA

Completed

Phase II Dose Titration Study in Patients With Neuropathic Pain

Neuropathic Pain

United Kingdom, Czech Republic, Poland, Italy, India, Austria
Newron Pharmaceuticals SPA
Parexel; CliniRx

Completed

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Pain

United Kingdom
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Prader-Willi Syndrome

United States
Nephron Pharmaceuticals Corporation

Completed

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Neuren Pharmaceuticals Limited

Completed

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Fragile X Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Female Subjects

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Neuren Pharmaceuticals Limited

Terminated

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Concussion

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC (INTREPID2566)

Brain Injuries

United States
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury (INTREPID2566)

Brain Injuries

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Recruiting

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, France
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Terminated

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Breast Cancer

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Terminated

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101)

HER2 Expressing Solid Tumours

United States, Germany
Neuren Pharmaceuticals Limited
rettsyndrome.org

Completed

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Rett Syndrome

United States
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Indonesia University
Ferron Par Pharmaceuticals

Completed

Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery

Cataract

Indonesia
Aquilon Pharmaceuticals S.A.

Completed

Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (BOREAS)

Asthma

Belgium
Amyndas Pharmaceuticals S.A.

Completed

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Complement Mediated Diseases

United States
Glenmark Pharmaceuticals S.A.

Completed

To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects

Healthy

United Kingdom
Aquilon Pharmaceuticals S.A.

Terminated

Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (SIROCCO-1)

Covid19

Belgium
Amyndas Pharmaceuticals S.A.

Completed

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

Gingivitis

United States
Aquilon Pharmaceuticals S.A.

Completed

Single-dose AQ001S PK Study in Healthy Volunteers (BORA)

Pharmacokinetics

Bulgaria
Amyndas Pharmaceuticals S.A.

Unknown

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) (SAVE)

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
APR Applied Pharma Research s.a.
Cavendish Impact Foundation; Clinigen, Inc.; Nephron Pharmaceuticals, Inc.

No longer available

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (SAMICARE)

Critical COVID-19 With Respiratory Failure

United States
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Completed

Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects

Healthy

United Kingdom

Clinical Trials Sponsored by Newron Pharmaceuticals SPA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations